A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-25

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis

NCT02063399

Nasopharyngeal Carcinoma

UNKNOWN

Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer

NCT01100814

Gastric Cancer

UNKNOWN

A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

NCT00186433

Mouth Cancer Lip Cancer Throat Cancer +2 more

COMPLETED

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

NCT05581550

Nasopharyngeal Cancer Epstein-Barr Virus Related Carcinoma

COMPLETED NA

Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium

NCT01321892

Squamous Cell Carcinoma of the Oral Cavity Oropharynx Larynx +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Epitope exploration

Intervention Type DIAGNOSTIC_TEST

Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.

Control

Epitope exploration

Intervention Type DIAGNOSTIC_TEST

Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epitope exploration

Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Controls underwent physical examinations or primary NPC cases confirmed by pathology or cytology.
* If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th.
* If cases, Karnofsky score (KFS)≥70, estimated survival span\>12 months.
* If cases, no disordered of major organs is found; blood test, liver, and kidney functions are basically normal.
* If cases, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.

Exclusion Criteria

* History of other malignant diseases.
* History of severe systemic diseases or heart, lung, liver, or kidney disfunction.
* History of severe neurological, metal, endocrine diseases.
* History of HBV, HCV, HIV, TP, or TB infection.
* If controls, physical examination reveals systemic diseases including malignant diseases.
* If cases, incomplete blood and pathological sample data.
* If cases, not receiving primary treatment in this facility.
* Other individuals investigators find not suitable for the trial.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes